Literature DB >> 25765191

The Use of Antidepressant Medication before and after the Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Cohort Study.

Federica Edith Pisa1, Giancarlo Logroscino, Anica Casetta, Laura Cecotti, Lorenzo Verriello, Alessio Bratina, Arianna Sartori, Lucio Lazzarino de Lorenzo, Roberto Eleopra, Fabio Barbone.   

Abstract

BACKGROUND: The prevalent use of antidepressants (ATDs) in patients with Amyotrophic Lateral Sclerosis (ALS) varies across cross-sectional and clinic-based published studies. This population-based cohort study assesses the real-world prevalence of the use of ATDs, its trajectory and the association of incident use with clinical characteristics.
METHODS: All patients with incident ALS in the Friuli Venezia Giulia region, Italy, from 2002 to 2009, were identified through multiple sources including health databases. Diagnosis was validated through clinical documentation review. ATDs prescriptions from 2000 to 2011 were obtained from regional database. The trajectory was estimated through generalized estimating equations for repeated measures logistic regression and the Hazard ratio (HR) of initiating ATDs through multivariate proportional hazard Cox regression.
RESULTS: In this cohort of 261 ALS cases, age-, sex-adjusted prevalence of the use of ATDs was 37.3%, higher than in general population. The trajectory increased by 16% in 1-year period across diagnosis. Age ≤67 years at diagnosis (HR 1.28, 95% CI 0.84-1.95) and bulbar onset (1.43, 95% CI 0.90-2.26) were positively associated with initiating ATDs after diagnosis.
CONCLUSIONS: More than one-third of patients used ATDs. Depression may occur more frequently than previously reported. Depression may precede motor alterations and be related to both ALS diagnosis and progression.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25765191     DOI: 10.1159/000374119

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  5 in total

1.  Anti-inflammatory therapies of amyotrophic lateral sclerosis guided by immune pathways.

Authors:  Larry Lam; Ramesh C Halder; Dennis J Montoya; Liudmilla Rubbi; Arturo Rinaldi; Bien Sagong; Sarah Weitzman; Rachel Rubattino; Ram Raj Singh; Matteo Pellegrini; Milan Fiala
Journal:  Am J Neurodegener Dis       Date:  2015-12-28

2.  Depression in amyotrophic lateral sclerosis.

Authors:  Elin Roos; Daniela Mariosa; Caroline Ingre; Cecilia Lundholm; Karin Wirdefeldt; Per M Roos; Fang Fang
Journal:  Neurology       Date:  2016-04-22       Impact factor: 9.910

3.  How complete is the information on preadmission psychotropic medications in inpatients with dementia? A comparison of hospital medical records with dispensing data.

Authors:  Federica Edith Pisa; Francesca Palese; Federico Romanese; Fabio Barbone; Giancarlo Logroscino; Oliver Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2018-06-05       Impact factor: 4.035

4.  Association between depression and survival in Chinese amyotrophic lateral sclerosis patients.

Authors:  Qianqian Wei; Zhenzhen Zheng; Xiaoyan Guo; Ruwei Ou; Xueping Chen; Rui Huang; Jing Yang; Huifang Shang
Journal:  Neurol Sci       Date:  2016-01-13       Impact factor: 3.307

5.  Perception of Emotional Facial Expressions in Amyotrophic Lateral Sclerosis (ALS) at Behavioural and Brain Metabolic Level.

Authors:  Helena E A Aho-Özhan; Jürgen Keller; Johanna Heimrath; Ingo Uttner; Jan Kassubek; Niels Birbaumer; Albert C Ludolph; Dorothée Lulé
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.